

Clinical Trials registered on ClinicalTrials.gov - Accessed 13th July, 2018

Rank	Status	Study
1	Withdrawn	<a href="#">Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer</a>
		<b>Condition:</b> Hepatocellular Cancer <b>Interventions:</b> Drug: Sorafenib; Radiation: yttrium-90 radioembolization
2	Recruiting	<a href="#">Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study</a>
		<b>Condition:</b> Neuroendocrine Tumors <b>Intervention:</b> Device: Holmium-166 microspheres hepatic radioembolization.
3	Active, not recruiting	<a href="#">Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases</a>
		<b>Condition:</b> Neuroendocrine Tumors <b>Interventions:</b> Drug: Pasireotide; Procedure: Sir-sphere Radioembolization; Drug: Everolimus
4	Unknown	<a href="#">Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma</a>
		<b>Condition:</b> Hepatocellular Carcinoma <b>Interventions:</b> Procedure: Transarterial Radioembolization; Procedure: Transarterial Chemoembolization using drug-eluting beads
5	Recruiting	<a href="#">Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma</a>
		<b>Condition:</b> HepatoCellular Carcinoma <b>Interventions:</b> Radiation: Y-90 Radioembolization; Drug: Nivolumab
6	Recruiting	<a href="#">Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases</a>
		<b>Conditions:</b> Colon Cancer; Rectal Cancer; Liver Metastases <b>Interventions:</b> Drug: Tas-102; Device: SIR-Sphere
7	Recruiting	<a href="#">Feasibility of Single Session In-Room Yttrium-90 Radioembolization Diagnostic Angiography and Treatment</a>
		<b>Conditions:</b> Malignant Neoplasms of Digestive Organs; Metastatic Liver Tumors <b>Intervention:</b> Device: SIR-Spheres
8	Recruiting	<a href="#">Local Ablative Strategies After Endovascular Radioembolization (LASER)</a>
		<b>Condition:</b> Metastatic Colorectal Cancer <b>Interventions:</b> Device: PET/MRI; Radiation: Percutaneous microwave ablation; Radiation: Stereotactic body radiotherapy
9	Completed	<a href="#">Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma</a>
		<b>Condition:</b> Ocular Melanoma <b>Interventions:</b> Drug: Sorafenib; Device: Radioembolization with SIR-Spheres® (Yttrium Microspheres)
10	Active, not recruiting	<a href="#">PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer</a>
		<b>Conditions:</b> Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Metastatic Extrahepatic Bile Duct Cancer; Recurrent Adult Primary Liver Cancer; Recurrent Extrahepatic Bile Duct Cancer; Stage D Adult Primary Liver Cancer (BCLC); Unspecified Adult Solid Tumor, Protocol Specific <b>Interventions:</b> Procedure: PET scan; Procedure: CT Scan; Procedure: hepatic artery embolization
11	Unknown †	<a href="#">Metastatic Colorectal Cancer Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization in the USA Evaluation Project</a>
		<b>Conditions:</b> Colorectal Cancer; Liver Metastases <b>Intervention:</b>
12	Unknown	<a href="#">Transarterial Radioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC)</a>
		<b>Condition:</b> Hepatocellular Carcinoma <b>Interventions:</b> Drug: TACE-DEB; Drug: 90Y-RE
13	Recruiting	<a href="#">Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization</a>
		<b>Conditions:</b> Colorectal Neoplasms; Neoplasm Metastasis; Liver Diseases; Digestive System Neoplasms <b>Intervention:</b> Device: Holmium-166-poly (L-lactic acid) microspheres
14	Terminated	<a href="#">Microsphere Localization Using Image Result for Positron Emission Tomography-Magnetic Resonance Imaging (PET/MRI) or Positron Emission Tomography-Computed Tomography (PET/CT) in Patients With Liver Disease</a>
		<b>Condition:</b> Liver Neoplasms <b>Interventions:</b> Device: PET/MR; Device: PET/CT
15	Active, not recruiting	<a href="#">Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres</a>
		<b>Conditions:</b> Neuroendocrine Tumors; Gastrointestinal Neoplasms; Carcinoid Tumors <b>Interventions:</b> Drug: Lanreotide; Device: Y-90 microspheres

16	Completed	<a href="#">Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases</a>	
		<b>Condition:</b>	Colorectal Neoplasms
17	Unknown	<a href="#">Pair Production PET Imaging to Detect Particle Distribution in Patients Undergoing Yttrium-90 Radioembolization</a>	
		<b>Condition:</b>	Carcinoma, Hepatocellular
18	Active, not recruiting	<a href="#">Prospective Post Y90 Liver Hypertrophy</a>	
		<b>Conditions:</b>	Hepatocellular Carcinoma; Liver Hypertrophy
19	Active, not recruiting	<a href="#">Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT</a>	
		<b>Interventions:</b>	Procedure: positron emission tomography; Procedure: computed tomography
20	Recruiting	<a href="#">Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis</a>	
		<b>Condition:</b>	Uveal Melanoma
21	Recruiting	<a href="#">Correlation Between CT Perfusion and Post Y-90 TARE PET/CT Dosimetry</a>	
		<b>Interventions:</b>	Radiation: CT Liver Perfusion; Radiation: PET/CT of liver
22	Completed	<a href="#">Interest of Functional MRI (Magnetic Resonance Imagery) (in Patients Suffering From Hepatocellular Carcinoma and Treated With Yttrium</a>	
		<b>Intervention:</b>	Other: Additional RMIs
23	Active, not recruiting	<a href="#">Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver</a>	
		<b>Interventions:</b>	Procedure: RFA; Procedure: Radioembolization (SIRT)
24	Recruiting	<a href="#">CIRSE Registry for SIR-Spheres Therapy</a>	
		<b>Interventions:</b>	Device: Yttrium-90 loaded SIR-Spheres microspheres; Behavioral: QLQ-C30 with HCC module
25	Recruiting	<a href="#">90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma</a>	
		<b>Interventions:</b>	Device: SIR-Spheres microspheres (Yttrium-90 Microspheres); Drug: Gemcitabine; Drug: Cisplatin
26	Recruiting	<a href="#">Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer</a>	
		<b>Interventions:</b>	Device: HAI-90Y radioembolization (SIR-spheres injection); Drug: systemic chemotherapy LV5FU2
27	Recruiting	<a href="#">Lung Dose in Patients Treated With Yttrium-90 for Hepatocellular Carcinoma</a>	
		<b>Intervention:</b>	
28	Not yet recruiting	<a href="#">Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver</a>	
		<b>Interventions:</b>	Biological: Durvalumab; Other: Laboratory Biomarker Analysis; Biological: Tremelimumab
29	Recruiting	<a href="#">Definitive Therapy for Oligometastatic Solid Malignancies</a>	
		<b>Interventions:</b>	Procedure: Complete Surgical Removal; Radiation: Stereotactic Radiosurgery; Radiation: Ablative external beam radiation dose; Procedure: Subtotal surgical removal plus ablative radiation dose; Radiation: Radioembolization
30	Completed	<a href="#">Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma</a>	
		<b>Intervention:</b>	Radiation: Therasphere® in association with Gemcitabine and Cisplatin
31	Active, not recruiting	<a href="#">Internal Radiation Therapy for Hepatocellular Carcinomas With Therasphere: Optimized Dosimetry Versus Standard Dosimetry</a>	
		<b>Interventions:</b>	Radiation: Optimized Internal Radiation Therapy; Radiation: Standard Internal Radiation Therapy

32	Recruiting	<a href="#">Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).</a>	<b>Condition:</b> Intrahepatic Cholangiocellular Carcinoma
		<b>Interventions:</b> Procedure: DEB TACE; Procedure: SIRT	
33	Unknown	<a href="#">PERfusion CT in the FOXFIRE Trial to Study Blood Flow to Liver Metastases</a>	<b>Condition:</b> Metastatic Colorectal Cancer
		<b>Intervention:</b> Other: Perfusion CT scan	
34	Recruiting	<a href="#">Prospective Tumor Response Evaluation</a>	<b>Conditions:</b> Hepatocellular Cancer; Metastatic Liver Cancer
		<b>Interventions:</b> Procedure: TACE; Procedure: Y-90; Procedure: MWA; Procedure: IRE	
35	Unknown	<a href="#">Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma</a>	<b>Condition:</b> Hepatocellular Carcinoma
		<b>Interventions:</b> Procedure: Transarterial Radioembolization; Procedure: Transarterial Chemoembolization using drug-eluting beads	
36	Withdrawn	<a href="#">Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer</a>	<b>Condition:</b> Hepatocellular Cancer
		<b>Interventions:</b> Drug: Sorafenib; Radiation: yttrium-90 radioembolization	
37	Unknown	<a href="#">Transarterial Radioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC)</a>	<b>Condition:</b> Hepatocellular Carcinoma
		<b>Interventions:</b> Drug: TACE-DEB; Drug: 90Y-RE	
38	Recruiting	<a href="#">90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma</a>	<b>Condition:</b> Intrahepatic Cholangiocarcinoma
		<b>Interventions:</b> Device: SIR-Spheres microspheres (Yttrium-90 Microspheres); Drug: Gemcitabine; Drug: Cisplatin	
39	Recruiting	<a href="#">Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis</a>	<b>Condition:</b> Uveal Melanoma
		<b>Interventions:</b> Procedure: SIRT; Procedure: DSM-TACE	
40	Recruiting	<a href="#">Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).</a>	<b>Condition:</b> Intrahepatic Cholangiocellular Carcinoma
		<b>Interventions:</b> Procedure: DEB TACE; Procedure: SIRT	
41	Recruiting	<a href="#">90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma</a>	<b>Condition:</b> Intrahepatic Cholangiocarcinoma
		<b>Interventions:</b> Device: SIR-Spheres microspheres (Yttrium-90 Microspheres); Drug: Gemcitabine; Drug: Cisplatin	
42	Recruiting	<a href="#">11C-Choline PET/CT and DWI MRI for Response Assessment of HCC Candidate to TARE</a>	<b>Condition:</b> Hepatocarcinoma
		<b>Intervention:</b> Other: No intervention	
43	Unknown	<a href="#">Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma</a>	<b>Condition:</b> Hepatocellular Carcinoma
		<b>Interventions:</b> Procedure: Transarterial Radioembolization; Procedure: Transarterial Chemoembolization using drug-eluting beads	
44	Withdrawn	<a href="#">Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer</a>	<b>Condition:</b> Hepatocellular Cancer
		<b>Interventions:</b> Drug: Sorafenib; Radiation: yttrium-90 radioembolization	
45	Recruiting	<a href="#">Correlation Between CT Perfusion and Post Y-90 TARE PET/CT Dosimetry</a>	<b>Condition:</b> Hepatocellular Carcinoma
		<b>Interventions:</b> Radiation: CT Liver Perfusion; Radiation: PET/CT of liver	
46	Recruiting	<a href="#">Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment</a>	<b>Condition:</b> Intrahepatic Cholangiocellular Carcinoma
		<b>Interventions:</b> Procedure: DEB TACE; Procedure: SIRT	
47	Recruiting	<a href="#">Treatment for Bile Duct Cancer in the Liver</a>	<b>Condition:</b> Cholangio Carcinoma
		<b>Intervention:</b> Drug: SIRT Yttrium-90	
48	Active, not recruiting	<a href="#">Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced</a>	<b>Condition:</b> Hepatocellular Carcinoma
		<b>Interventions:</b> Device: SIR-Spheres; Drug: Sorafenib tosylate	
49	Active, not recruiting	<a href="#">Internal Radiation Therapy for Hepatocellular Carcinomas With Therasphere: Optimized Dosimetry Versus</a>	<b>Condition:</b> Adenoma, Liver Cell
		<b>Interventions:</b> Radiation: Optimized Internal Radiation Therapy; Radiation: Standard Internal Radiation Therapy	
50	Active, not recruiting	<a href="#">CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases</a>	<b>Condition:</b> Liver Metastases
		<b>Interventions:</b> Biological: anti-CEA CAR-T cells; Device: Sir-Spheres	



51	Recruiting	<a href="#">SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of</a>	<b>Condition:</b> Intrahepatic Cholangiocarcinoma
		<b>Interventions:</b> Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)	
52	Active, not recruiting	<a href="#">Prospective Post Y90 Liver Hypertrophy</a>	<b>Conditions:</b> Hepatocellular Carcinoma; Liver Hypertrophy
		<b>Intervention:</b> Other: CT volumetric measurement after Y90 radioembolization	
53	Recruiting	<a href="#">CIRSE Registry for SIR-Spheres Therapy</a>	<b>Condition:</b> Liver Carcinoma
		<b>Interventions:</b> Device: Yttrium-90 loaded SIR-Spheres microspheres; Behavioral: QLQ-C30 with HCC module	
54	Recruiting	<a href="#">Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma</a>	<b>Condition:</b> HepatoCellular Carcinoma
		<b>Interventions:</b> Radiation: Y-90 Radioembolization; Drug: Nivolumab	
55	Active, not recruiting	<a href="#">FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary</a>	<b>Condition:</b> Colorectal Cancer Metastatic
		<b>Interventions:</b> Drug: FOLFOX6m; Device: SIR-Spheres microspheres	
56	Unknown	<a href="#">Internal Radiation Therapy With Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and</a>	<b>Conditions:</b> Metastatic Cancer; Pancreatic Cancer
		<b>Interventions:</b> Drug: fluorouracil; Radiation: selective external radiation therapy; Radiation: tomotherapy; Radiation: yttrium Y 90 glass microspheres; Radiation: yttrium Y 90 resin microspheres	
57	Active, not recruiting	<a href="#">Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are</a>	<b>Conditions:</b> Neuroendocrine Tumors; Gastrointestinal Neoplasms; Carcinoid Tumors
		<b>Interventions:</b> Drug: Lanreotide; Device: Y-90 microspheres	
58	Active, not recruiting	<a href="#">SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver</a>	<b>Condition:</b> Stage IV Uveal Melanoma
		<b>Intervention:</b> Device: Sir-Spheres®	
59	Active, not recruiting	<a href="#">Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT</a>	<b>Conditions:</b> Advanced Adult Primary Liver Cancer; Liver Metastases; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer
		<b>Interventions:</b> Procedure: positron emission tomography; Procedure: computed tomography	
60	Terminated	<a href="#">Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein</a>	<b>Condition:</b> Hepatocellular Carcinoma
		<b>Interventions:</b> Device: TheraSphere; Drug: Sorafenib	
61	Active, not recruiting	<a href="#">Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or</a>	<b>Conditions:</b> Liver Cancer; Metastatic Cancer
		<b>Interventions:</b> Drug: capecitabine; Radiation: yttrium Y 90 glass microspheres	
62	Recruiting	<a href="#">Lung Dose in Patients Treated With Yttrium-90 for Hepatocellular Carcinoma</a>	<b>Condition:</b> Liver Neoplasms
		<b>Intervention:</b>	
63	Active, not recruiting	<a href="#">Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced</a>	<b>Condition:</b> Hepatocellular Carcinoma
		<b>Interventions:</b> Device: SIR-Spheres; Drug: Sorafenib tosylate	
64	Recruiting	<a href="#">Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma</a>	<b>Condition:</b> Uveal Melanoma
		<b>Interventions:</b> Procedure: SIRT; Procedure: DSM-TACE	
65	Active, not recruiting	<a href="#">Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma (HCC)</a>	<b>Condition:</b> Liver Cancer
		<b>Interventions:</b> Drug: Sorafenib; Radiation: Yttrium-90 Microspheres; Behavioral: Follow-Up Phone Calls	
66	Active, not recruiting	<a href="#">CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases</a>	<b>Condition:</b> Liver Metastases
		<b>Interventions:</b> Biological: anti-CEA CAR-T cells; Device: Sir-Spheres	
67	Completed	<a href="#">FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary</a>	<b>Conditions:</b> Colorectal Cancer; Colorectal Carcinoma; Liver Metastases
		<b>Interventions:</b> Drug: Systemic chemotherapy (FOLFOX); Device: SIR-Spheres yttrium-90 microspheres	
68	Active, not recruiting	<a href="#">Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer</a>	<b>Condition:</b> Unresectable Hepatocellular Carcinoma
		<b>Intervention:</b> Device: TheraSphere	
69	Recruiting	<a href="#">Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal</a>	<b>Condition:</b> Colorectal Cancer Metastatic
		<b>Intervention:</b> Device: TheraSphere	
70	Withdrawn	<a href="#">Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be</a>	<b>Condition:</b> Liver Cancer
		<b>Intervention:</b> Radiation: yttrium Y 90 glass microspheres	
71	Recruiting	<a href="#">90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic</a>	<b>Condition:</b> Intrahepatic Cholangiocarcinoma
		<b>Interventions:</b> Device: SIR-Spheres microspheres (Yttrium-90 Microspheres); Drug: Gemcitabine; Drug: Cisplatin	

72	Active, not recruiting	<a href="#">Internal Radiation Therapy for Hepatocellular Carcinomas With Therasphere: Optimized Dosimetry Versus</a>	
		<b>Condition:</b>	Adenoma, Liver Cell
73	Unknown	<a href="#">Transarterial Radioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular</a>	
		<b>Condition:</b>	Hepatocellular Carcinoma
74	Recruiting	<a href="#">Yttrium90, Ipilimumab, &amp; Nivolumab for Uveal Melanoma With Liver Metastases</a>	
		<b>Interventions:</b>	Radiation: Optimized Internal Radiation Therapy; Radiation: Standard Internal Radiation Therapy
75	Recruiting	<a href="#">Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver</a>	
		<b>Interventions:</b>	Drug: TACE-DEB; Drug: 90Y-RE
76	Recruiting	<a href="#">Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study</a>	
		<b>Intervention:</b>	Other: Yttrium-90 Resin Microspheres
77	Recruiting	<a href="#">Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer</a>	
		<b>Conditions:</b>	Stage IIIA Hepatocellular Carcinoma; Stage IIIB Hepatocellular Carcinoma; Stage IIIC Hepatocellular Carcinoma; Stage IVA Hepatocellular Carcinoma; Stage IVB Hepatocellular Carcinoma
78	Unknown	<a href="#">Metastatic Colorectal Cancer Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization</a>	
		<b>Intervention:</b>	Other: Laboratory Biomarker Analysis; Biological: Nivolumab; Radiation: Yttrium Y 90 Glass Microspheres
79	Recruiting	<a href="#">Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal</a>	
		<b>Interventions:</b>	Device: HAI-90Y radioembolization (SIR-spheres injection); Drug: systemic chemotherapy LV5FU2
80	Completed	<a href="#">Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With</a>	
		<b>Interventions:</b>	Device: SIR-Spheres; Drug: Regorafenib
81	Withdrawn	<a href="#">Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced</a>	
		<b>Interventions:</b>	Drug: Sorafenib; Radiation: yttrium-90 radioembolization
82	Completed	<a href="#">Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous</a>	
		<b>Intervention:</b>	Radiation: Therasphere® in association with Gemcitabine and Cisplatin
83	Recruiting	<a href="#">Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery</a>	
		<b>Interventions:</b>	Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis
84	Not yet recruiting	<a href="#">SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of</a>	
		<b>Interventions:</b>	Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
85	Terminated	<a href="#">Microsphere Localization Using Image Result for Positron Emission Tomography-Magnetic Resonance</a>	
		<b>Interventions:</b>	Device: PET/MR; Device: PET/CT
86	Recruiting	<a href="#">Treatment for Bile Duct Cancer in the Liver</a>	
		<b>Intervention:</b>	Drug: SIRT Yttrium-90
87	Completed	<a href="#">Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors</a>	
		<b>Intervention:</b>	Device: TheraSphere, Yttrium-90 glass Microspheres
88	Unknown	<a href="#">Internal Radiation Therapy With Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and</a>	
		<b>Interventions:</b>	Drug: fluorouracil; Radiation: selective external radiation therapy; Radiation: tomotherapy; Radiation: yttrium Y 90 glass microspheres; Radiation: yttrium Y 90 resin microspheres
89	Enrolling by invitation	<a href="#">Radiolabeled Glass Beads Used for Treating Patients With Primary Liver Cancer When Surgery is Not an</a>	
		<b>Intervention:</b>	Device: Yttrium 90 (TheraSphere)
90	Recruiting	<a href="#">Humanitarian Device Exemption (HDE) Treatment Protocol For Treatment of Unresectable Hepatocellular</a>	
		<b>Intervention:</b>	Device: TheraSphere Treatment
91	Recruiting	<a href="#">Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery</a>	
		<b>Condition:</b>	Liver Cancer

		<b>Intervention:</b>	Radiation: yttrium Y 90 glass microspheres
92	Unknown	<b>Conditions:</b>	Colorectal Cancer; Metastatic Cancer
		<b>Interventions:</b>	Drug: floxuridine; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin
93	Unknown	<b>Condition:</b>	Hepatocellular Carcinoma
		<b>Interventions:</b>	Procedure: Transarterial Radioembolization; Procedure: Transarterial Chemoembolization using drug-eluting beads